Latest news with #24thAnnualNeedhamHealthcareConference
Associated Press
08-04-2025
- Business
- Associated Press
Sound Pharma to Present at Upcoming Life Science Investor Conferences
SEATTLE--(BUSINESS WIRE)--Apr 8, 2025-- Sound Pharmaceuticals is pleased to announce that it has been invited to present its R&D and financing goals at four upcoming life science and healthcare investor conferences over the next month. 24 th Annual Needham Healthcare Conference on April 9-10 25 th Life Sciences Innovation Northwest on April 23-24 Citibank Biotech Private Access Investor Day on April 24 Morgan Stanley Inaugural Private Company & Investor Day on May 5 Dr. Jonathan Kil, Co-Founder and CEO will provide an update on SPI-1005, the novel oral anti-inflammatory, the first investigational drug to achieve its co-primary endpoints in a pivotal Phase 3 randomized double blinded placebo-controlled trial (RCTs) to treat Meniere's disease (STOPMD-3). There are no FDA approved drugs for the treatment of hearing loss, tinnitus, dizziness or vertigo, the primary symptoms of MD. SPI-1005 has achieved positive safety and efficacy results in five different RCTs involving MD, acute noise-induced hearing loss, and aminoglycoside-induced ototoxicity. About SPI-1005 SPI-1005 is an investigational new drug that contains ebselen, a new chemical entity that mimics and induces glutathione peroxidase (GPx) activity. GPx1 is a critical enzyme that repairs injured and dying cells in the inner ear, retina, prefrontal cortex of brain, lung, and kidney, and is often reduced during and after exposure to environmental insults or aging. Consequently, neuroinflammation can progress throughout the peripheral and central nervous system leading to neurodegeneration. SPI-1005 is being developed for several neurotologic indications including Meniere's disease (hearing loss, tinnitus, intermittent dizziness, and episodic vertigo), noise-induced hearing loss (including tinnitus) and two types of ototoxicity (hearing loss, tinnitus, dizziness, or vertigo) caused by aminoglycoside antibiotics (such as tobramycin or amikacin) or platinum-based chemotherapy (such as cisplatin or carboplatin). To date, no significant drug-drug interactions have been observed across multiple study populations including Meniere's disease, and patients with cystic fibrosis, bipolar mania, and treatment-resistant depression. Thirteen SPI-1005 trials have been completed treating 790 patients with 400+ more anticipated later this year. About Sound Pharmaceuticals Sound Pharma is a private biotechnology company studying SPI-1005 under six active Investigational New Drug Applications involving several neurotologic indications including the prevention and treatment of aminoglycoside-induced ototoxicity co-funded by the Cystic Fibrosis Foundation and hearing preservation in cochlear implant patients co-funded by MED-EL. Details of the SPI-1005 clinical trials can be viewed online at or Please contact [email protected] for further information. SOURCE: Sound Pharmaceuticals Copyright Business Wire 2025. PUB: 04/08/2025 09:10 AM/DISC: 04/08/2025 09:10 AM
Yahoo
01-04-2025
- Business
- Yahoo
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference
STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025. Details of the event are as follows:Fireside Chat Date and Time: Tuesday, April 8, 2025, at 9:30 a.m. ET The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Collegium Pharmaceutical, is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM®, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium's strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium's headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company's website at Investor Contacts:Ian KarpHead of Investor Relationsir@ Danielle JesseDirector, Investor Relationsir@ Media Contact:Cheryl WheelerHead of Corporate Communicationscommunications@ in to access your portfolio
Yahoo
31-03-2025
- Business
- Yahoo
Seaport Therapeutics to Participate in Upcoming Investor Conferences in April
BOSTON, March 31, 2025--(BUSINESS WIRE)--Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that members of its management team will participate in the following upcoming investor conferences: 24th Annual Needham Healthcare Conference The Seaport management team was invited to present on Monday, April 7th at 3:45pm EDT. The live and archived webcast will be available under the Events section of the Company's website at Management will also participate in one-on-one meetings at the conference. Citi Biotech Private Access Day The Seaport management team was invited to participate in one-on-one meetings at the virtual conference on April 24th. About Seaport Therapeutics Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph™ technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and is guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit View source version on Contacts Public Relationspublicrelations@ Investor Relationsir@
Yahoo
25-03-2025
- Business
- Yahoo
Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th
MENLO PARK, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ('Sight Sciences' or the 'Company'), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the 24th Annual Needham Healthcare Conference being held virtually. Sight Sciences' management is scheduled to present on Tuesday, April 8, 2025, at 12:45 pm PT / 3:45 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the 'Investors' section of the Company's website at About Sight Sciences Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients' lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world's most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company's OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world's leading cause of irreversible blindness. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company's TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease ('MGD'), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit for more information. Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories. © 2025 Sight Sciences. All rights reserved. Media contact:pr@ Investor contact:Philip TaylorGilmartin in to access your portfolio
